<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00802217</url>
  </required_header>
  <id_info>
    <org_study_id>WL-1001-03-01</org_study_id>
    <nct_id>NCT00802217</nct_id>
  </id_info>
  <brief_title>Oral Civamide Safety, Tolerability First in Human Study</brief_title>
  <official_title>A Phase 1 Open-Label, Single-Dose, Dose Escalation Study in Healthy Subjects to Evaluate the Safety and Pharmacokinetics of Orally Administered Civamide (Zucapsaicin)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Winston Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Winston Laboratories</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and pharmacokinetic first-time-in-human study of orally administered civamide in&#xD;
      healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, non-randomized pharmacokinetic study of two dosage strengths of oral&#xD;
      Civamide. The study consists of a Screening Period (Days -21 to Day -2), an Admittance&#xD;
      Period, A 4 Day in-house Treatment Period(Days 1-4))and a follow-up Visit on Day 7.&#xD;
&#xD;
      Pharmacokinetics will be assessed at specified timepoints relative to dosing on Day 1 during&#xD;
      the in-house stay. Subjects will be discharged from the research unit following the 72 hr&#xD;
      blood draw.&#xD;
&#xD;
      Subjects will return to the research unit on Day 7 for a follow-up safety assessment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PK results demonstrated no systemic absorption&#xD;
  </why_stopped>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure the absorption of serum Civamide through pharmacokinetics assessments</measure>
    <time_frame>4 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Civamide liquid filled softgel capsule 5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Civamide liquid filled soft gel capsules 2 x 5 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Civamide</intervention_name>
    <description>5 mg liquid filled softgel capsules</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>oral civamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Civamide</intervention_name>
    <description>5 mg x 2 liquid softgel capsules</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>oral civamide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject voluntarily agrees to participate in this study and signs an IRB-approved&#xD;
             informed consent prior to performing any of the screening procedures.&#xD;
&#xD;
          2. Healthy, determined by pre-study medical evaluation (medical history and physical&#xD;
             examination, vital signs, ECG, and clinical laboratory evaluations).&#xD;
&#xD;
          3. Males or females between 18 to 45 years of age, inclusive.&#xD;
&#xD;
          4. Female subjects must be of nonchildbearing potential (surgically sterile [hysterectomy&#xD;
             or bilateral tubal ligation] or post-menopausal ≥ 1 year) with follicle stimulating&#xD;
             hormone [FSH] &gt; 40 U/L).&#xD;
&#xD;
          5. Non-smokers (or other nicotine use) as determined by history (no nicotine use over the&#xD;
             past year) and by urine cotinine concentration (&lt; 200 ng/ml) at screening and/or Day&#xD;
             -1.&#xD;
&#xD;
          6. Body mass index (BMI) between 18.5 and 30.5 kg/m2, inclusive, at screening.&#xD;
&#xD;
          7. Subject is willing and able to cooperate to the extent required by the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant history or evidence of cardiovascular, respiratory, hepatic,&#xD;
             renal, gastrointestinal, endocrine, neurological, immunological, or psychiatric&#xD;
             disorder(s) as determined by the Investigator or designee.&#xD;
&#xD;
          2. Subjects with a history or clinical findings of coronary artery disease/cardiovascular&#xD;
             disease or ECG findings judged clinically significant by the Investigator.&#xD;
&#xD;
          3. Any disorder that would interfere with the absorption, distribution, metabolism, or&#xD;
             excretion of drugs.&#xD;
&#xD;
          4. Subjects with active upper gastrointestinal problems such as gastroesophageal reflux&#xD;
             disease (GERD), or peptic ulcer disease.&#xD;
&#xD;
          5. Subject has known allergy or hypersensitivity to capsicum, Civamide, or&#xD;
             capsaicin-containing products.&#xD;
&#xD;
          6. Positive screening test for Hepatitis B surface antigen, Hepatitis C antibody, or HIV&#xD;
             antibody.&#xD;
&#xD;
          7. Subject has history of alcohol and/or illicit drug abuse within two years of entry.&#xD;
&#xD;
          8. Positive blood test for ethanol at screening or Day -1.&#xD;
&#xD;
          9. Positive urine drug test (cocaine, amphetamines, barbiturates, opiates,&#xD;
             benzodiazepines, tetrahydrocannabinol [THC], etc.) at screening or Day -1.&#xD;
&#xD;
         10. Female subjects of childbearing potential or who are pregnant or breastfeeding.&#xD;
&#xD;
         11. Inability to refrain from consumption of coffee and caffeine containing beverages&#xD;
             within 24 hours prior to Day -1 until discharge from the unit on Day 4.&#xD;
&#xD;
         12. Inability to refrain from use of alcohol or alcohol-containing foods, medications or&#xD;
             beverages within 48 hours prior to Day -1 until discharge from the unit on Day 4.&#xD;
&#xD;
         13. Topical use of any capsaicin-containing product for 60 days prior to Day -1 until end&#xD;
             of study participation.&#xD;
&#xD;
         14. Ingestion of any capsaicin-containing foods (capsicum, cayenne pepper, red pepper,&#xD;
             green pepper, Scotch Bonnet, Habanero peppers, African chilies, Tabasco peppers,&#xD;
             paprika, pimiento, Mexican chilies, Louisiana long pepper, Louisiana short pepper,&#xD;
             Bird pepper, Garden pepper, Goat's pod, Grains of Paradise, Hot pepper, Hungarian&#xD;
             Pepper, Ici Fructus, Sweet pepper, and Zanzibar pepper) for 48 hours before Day -1&#xD;
             until end of study participation.&#xD;
&#xD;
         15. Donation of blood (&gt; 250 ml) or blood products within 2 months (56 days) prior to Day&#xD;
             -1.&#xD;
&#xD;
         16. Consumption of grapefruit containing food/beverages or Seville oranges (orange&#xD;
             marmalade) from 7 days prior to Day -1 until discharge from the unit on Day 4.&#xD;
&#xD;
         17. Use of over the counter (OTC) medications (including vitamins), prescription&#xD;
             medications, or herbal remedies from the 14 days prior to Day -1 until discharge from&#xD;
             the unit on Day 4. By exception, acetaminophen £ 1 gram per day is permitted and&#xD;
             hormone replacement therapy is permitted.&#xD;
&#xD;
         18. Use of an investigational drug within 30 days prior to Day -1.&#xD;
&#xD;
         19. Unwilling to abstain from vigorous exercise from 48 hours prior to Day -1 until&#xD;
             discharge from the unit on Day 4.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott B Phillips, M D</last_name>
    <role>Study Director</role>
    <affiliation>Winston Laboratories</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shwe Gyaw, M D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parexel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel International, Inc.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>November 26, 2008</study_first_submitted>
  <study_first_submitted_qc>December 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2008</study_first_posted>
  <last_update_submitted>June 8, 2011</last_update_submitted>
  <last_update_submitted_qc>June 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Scott B. Phillips, M.D.</name_title>
    <organization>Winston Laboratories, Inc.</organization>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Healthy Volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capsaicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

